News
New Amsterdam Sciences Announces Collaboration with the University of Liverpool to perform additional supportive studies confirming NAS150’s efficacy to treat Rheumatoid Arthritis
NAS will utilize the collected data to support Phase 2 initiatives advancing NAS150 as an RA treatment alternative. The Company’s Platform of Inflammatory Reducing Therapeutics is also intended to be leveraged for the treatment of other autoimmune conditions including Multiple Sclerosis Binghamton, NY – January 5th 2022 — New Amsterdam Sciences, Read more…